Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$8.17M+374.85%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Albert A. Luderer
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 96
- Beta
- 1.65
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -22.15
Financials
Revenue
$8.17M+374.8%Net Income
$-7.42MEBITDA
$-5.12MFree Cash Flow
$-4.67MEPS (diluted)
$-0.64Shares Outstanding (diluted)
11.55M+69207.9%Operating Expenses
$11.53MCash & Debt
$9.92MRevenue by Segment (annual)
$55.25MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $28.51M | $-26.39M | $-4.85 |
| 2024 | $30.78M | $-112.02M | $-88.13 |
| 2023 | $36.12M | $-232.49M | $-408.48 |
| 2022 | $27.80M | $-132.60M | $-275.09 |
| 2021 | $17.98M | $-72.44M | $-157.02 |
| 2020 | $8.50M | $-41.11M | $-236.58 |
| 2019 | $10.13M | $-29.82M | $-1194.36 |
| 2018 | $12.00M | $-18.50M | $-1568.13 |
| 2017 | $9.51M | $-23.37M | $-1402.56 |
| 2016 | $6.79M | $-18.85M | $-1131.43 |
Valuation
BNGOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-16.67%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·13d ago·Neutral
…Mapping for Hematologic Malignancies SAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed test (LDTs), today announced expansion of optical genome mapping (OGM) based testing of hematologic malignancies at Memorial Sloan Kettering Cancer Center (MSK), following approval from the New York State Department of Health (NYSDOH).
View source ↗ - Newsglobenewswire.com·22d ago·Negative
Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid Leukemia Independent research teams at MD Anderson Cancer Center, the University of Oulu, and the Josep Carreras Leukaemia Research Institute report that optical genome mapping (OGM) uncovers clinically significant genomic alterations missed by conventional cytogenetics, with direct implications for risk stratification across MDS, AML
View source ↗ - Newsglobenewswire.com·28d ago·Neutral
Bionano Laboratories Announces New York State Department of Health Approval of Lab Developed Tests Based on Optical Genome Mapping New York State Department of Health approval allows clinical use of optical genome mapping (OGM) based lab developed tests (LDTs) for patients with suspected genetic disease, reproductive disorders, and hematologic malignancies at University of Rochester Medicine New York State Department of Health approval allows clinical use of optical genome mapping (OGM) based la
View source ↗ - Newsseekingalpha.com·56d ago·Positive
Bionano Genomics, Inc. (BNGO) Q2 2026 Earnings Call Transcript Bionano Genomics, Inc. (BNGO) Q2 2026 Earnings Call Transcript
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.45 per share
Typical surprise +12.2% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.64 vs $-0.67beat
- Wed, May 13$-0.76 vs $-0.81beat
- Mon, Mar 23$-0.03 vs $-0.81beat
- Thu, Nov 13$-1.59 vs $-1.81beat
- Thu, Aug 14$-1.99 vs $-2.69beat
- Wed, May 14$-1.15 vs $-3.49beat
Estimates and results for BNGO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BNGO officers and directors.
- Bought
- $10k
- Sold
- —
2 trades
0 trades
- Luderer Albertbought
- Luderer Albertbought
98 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BNGO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.